Reirradiation for Locoregional Recurrent Breast Cancer

医学 不良事件通用术语标准 四分位间距 不利影响 乳腺癌 放射治疗 核医学 癌症 内科学
作者
Sayeh Fattahi,Safia K. Ahmed,Sean S. Park,Ivy A. Petersen,Dean A. Shumway,Bradley J. Stish,Elizabeth Yan,Nicholas B. Remmes,Robert W. Mutter,Kimberly S. Corbin
出处
期刊:Advances in radiation oncology [Elsevier BV]
卷期号:6 (1): 100640-100640 被引量:37
标识
DOI:10.1016/j.adro.2020.100640
摘要

Reirradiation poses a distinct therapeutic challenge owing to risks associated with exceeding normal tissue tolerances and possibly more therapeutically resistant disease biology. We report our experience with reirradiation for locoregional recurrent or second primary breast cancer.Between 1999 and 2019, all patients with breast cancer treated with repeat breast/chest wall radiation therapy (RT) at our institution were identified. Adverse events were assessed using the Common Terminology Criteria for Adverse Events v5.0. Fisher exact, Mann-Whitney rank-sum, and unpaired t tests were used for statistical analysis. Freedom from locoregional recurrence and distant metastasis as well as overall survival were calculated using the Kaplan-Meier method.Seventy-two patients underwent reirradiation. Median prior RT dose, reirradiation dose, and cumulative dose were 60 Gy (interquartile range [IQR], 50-60.4 Gy), 45 Gy (IQR, 40-50 Gy), and 103.54 Gy2 (IQR, 95.04-109.62 Gy2), respectively. Median time between RT courses was 73 months (IQR, 29-129 months). Thirty-four patients (47%) had gross residual disease at time of reirradiation. Course intent was described as curative in 44 patients (61%) and palliative in 28 (39%). Fifty-two patients (72%) were treated with photons ± electrons and 20 (28%) with protons. With a median follow-up of 22 months (IQR, 10-43 months), grade 3 adverse events were experienced by 13% of patients (10% acute skin toxicity and 3% late skin necrosis). Time between RT courses and reirradiation fields was significantly associated with the development of grade 3 toxicity at any point. Proton therapy conferred a dosimetric advantage without difference in toxicity. At 2 years, locoregional recurrence-free survival was 74.6% and overall survival was 65.5% among all patients, and 93.1% and 76.8%, respectively, among curative intent patients treated without gross disease. Distant metastasis-free survival was 59.0% among all curative intent patients.Reirradiation for locoregional recurrent breast cancer is feasible with acceptable rates of toxicity. Disease control and survival are promising among curative intent reirradiation patients without gross disease.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Charles完成签到,获得积分10
2秒前
hao发布了新的文献求助10
2秒前
小嘎发布了新的文献求助10
2秒前
ABin完成签到,获得积分10
4秒前
Jasper应助qixiaoqi采纳,获得10
4秒前
FangyingTang完成签到 ,获得积分10
5秒前
金枪鱼子完成签到,获得积分10
5秒前
theyoung发布了新的文献求助10
5秒前
6秒前
量子星尘发布了新的文献求助10
6秒前
赘婿应助liu采纳,获得10
6秒前
小马甲应助清仔采纳,获得10
6秒前
6秒前
luoyue完成签到,获得积分10
6秒前
yuan发布了新的文献求助10
7秒前
科研通AI5应助JR采纳,获得30
7秒前
8秒前
海阔天空发布了新的文献求助10
9秒前
SYLH应助WangZhen采纳,获得10
9秒前
票子发布了新的文献求助10
9秒前
苹果柜子完成签到 ,获得积分10
9秒前
活泼的平灵完成签到,获得积分10
10秒前
愤怒的咖啡完成签到,获得积分10
10秒前
愉快的银耳汤完成签到,获得积分10
11秒前
又又完成签到,获得积分10
12秒前
ypres完成签到 ,获得积分10
13秒前
13秒前
13秒前
zzzk完成签到 ,获得积分10
13秒前
酒精过敏完成签到,获得积分10
13秒前
席冥完成签到,获得积分10
15秒前
16秒前
搜集达人应助可乐采纳,获得10
16秒前
17秒前
清仔发布了新的文献求助10
17秒前
kevin发布了新的文献求助10
18秒前
飘逸怜菡完成签到 ,获得积分10
18秒前
单身的钧完成签到,获得积分10
19秒前
19秒前
久伴久爱完成签到 ,获得积分10
19秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038619
求助须知:如何正确求助?哪些是违规求助? 3576294
关于积分的说明 11375058
捐赠科研通 3306084
什么是DOI,文献DOI怎么找? 1819374
邀请新用户注册赠送积分活动 892698
科研通“疑难数据库(出版商)”最低求助积分说明 815066